Review BioFIT 2019: A great first edition in Marseille
For its first phocean edition, BioFIT confirms its status as the leading European partnering event for early-stage deals and investment rounds in the Life Sciences field. Over 1,150 attendees from over 35 countries attended BioFITs 8th edition: 120+ exhibitors, 70 speakers, 16 conferences and 4 projects elected as the most innovative in their categories were gathered in Marseille at Parc Chanot on December 10th and 11th.
A successful first edition in the South of France for BioFIT
Organised by Eurasanté and the three competitiveness clusters, the NHL Clubster, BioValley France and Eurobiomed, BioFIT was held for its 8th edition in Marseille, and has gathered more than 1,150 participants from more than 35 countries. TTOs, research institutions, academics, pharma & diagnostic companies, emerging biotech companies, preclinical CROs and CDMOs, pre-seed, seed and Series A investors were there to discover the latest trends of the sector and contribute to develop tomorrows innovative products and services in the Life Sciences sector.
Launched in 2010 in Lille, BioFIT enables partnerships between big companies and start-ups/big companies and academic actors in the field of Life Sciences. BioFIT is also the place for start-ups, technologies, offers and animal health projects to find investment opportunities by pitching in front of investors and big companies. BioFIT was created to encourage academic and industrial actors to build partnerships, to source innovative and competitive early-stage deals, to facilitate the emergence of collaborative projects, to increase licensing opportunities, to obtain funding and to facilitate market access.
For two days, overs 13,000 meetings had been generated through the partnering activity: the one-to-one meetings, which is the most efficient way to identify and connect with future project partners, obtain funding and then accelerate innovation.
MediSieve Ltd., elected as the most innovative start-up
Among 50 applications, 19 start-ups were selected to pitch during the Start-up Slams at BioFIT in different categories such as cell-therapy, cardio-metabolic, wound-care, animal health, cancer and CNS. MediSieve Ltd., an English start-up represented by George Frodsham, founder and CEO, is the winner of this years edition of the Start-up Slams, from the cancer category.
ALCEDIAG, elected as the most promising technology
35 TTOs, universities, research institutes and companies applied to the Collaborative and Licensing Opportunity Presentations to showcase their technology in front of potential partners in order to entail a collaborative project and / or a licensing deal. 9 of them have been selected to pitch during BioFIT in 4 different categories: diagnostic, CNS, cell-therapy and infection. ALCEDIAG, represented by Marianne Morini, Business Development Manager, received the Most promising Technology award.
Velabs Therapeutics GmbH, elected as the most innovative offer
11 innovative offers have been selected among service providers and technology platforms that applied to the Service Presentations. They showcased their offer in front of potential clients. Velabs Therapeutics, represented by Dr. Christoph Antz, Managing Director, received the Most innovative offer award.
AND BioPharma, elected as the most innovative animal health project
3 innovative animal health projects have been selected among companies that applied to the Animal Health Collaborative Opportunity Presentations and showcased their project in front of potential partners and investors. AND BioPharma, a Belgium project represented by Peter Jens, CEO and Business Development, is the winner of this years edition of the Animal Health Collaborative Opportunity Presentations.
Contact:
Valentine Delabie
Event Communication Officer
+33 (0) 3 28 55 90 60
vdelabie@eurasante.com
Biocytogen Co Ltd
Draupnir Bio ApS